ZMIZ2 and hepatocellular carcinoma: Our research found that HCC patients with high ZMIZ2 expression had higher mutation rate of TP53 and poorer overall survival outcomes, suggesting that ZMIZ2 overexpression and TP53 mutations may jointly affect the development and prognosis of HCC.